Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
Source: View publication →
In patients with previously treated advanced or metastatic non-small cell lung cancer (NSCLC), datopotamab deruxtecan demonstrated a statistically significant improvement in progression-free survival (PFS) compared with docetaxel, particularly in the nonsquamous subgroup, though it did not significantly improve overall survival (OS).
Key Findings
Study Design
Study Limitations
Clinical Significance
While Dato-DXd offers a statistically significant improvement in PFS over docetaxel and a more manageable grade ≥3 toxicity profile in pretreated NSCLC, the lack of significant OS benefit necessitates careful selection of patients—likely favoring those with nonsquamous histology—when considering this therapy in clinical practice.
Historical Context
Docetaxel has long served as the standard-of-care second-line chemotherapy for patients with advanced NSCLC who progress after initial platinum-based treatment; however, its use is often limited by significant toxicities and modest efficacy, prompting the evaluation of newer targeted agents like the TROP2-directed antibody-drug conjugate datopotamab deruxtecan.
Guided Discussion
High-yield insights from every perspective
What is the mechanism of action of datopotamab deruxtecan (Dato-DXd), and how does its 'bystander effect' distinguish it from traditional chemotherapy?
Key Response
Dato-DXd is an antibody-drug conjugate (ADC) consisting of a humanized anti-TROP2 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload (deruxtecan). Unlike traditional chemotherapy which affects all rapidly dividing cells, ADCs deliver the cytotoxic agent directly to cells expressing the target antigen (TROP2). The 'bystander effect' occurs when the payload is released from the target cell and diffuses into neighboring tumor cells, potentially killing adjacent cells regardless of their target expression, which is a key feature of the deruxtecan-based ADC technology.
In the TROPION-Lung01 study, how did the toxicity profile of datopotamab deruxtecan differ from docetaxel, and what are the key adverse events a clinician must monitor for?
Key Response
Datopotamab deruxtecan showed a different safety profile than docetaxel. While docetaxel is associated with higher rates of grade 3 or higher neutropenia and febrile neutropenia, Dato-DXd is more commonly associated with stomatitis (all grades ~47%) and nausea. Critically, clinicians must monitor for interstitial lung disease (ILD)/pneumonitis, a known class effect of deruxtecan ADCs, which occurred in 8% of patients in the Dato-DXd arm (mostly low grade, but including some fatal cases).
How should the significant progression-free survival (PFS) benefit observed in the nonsquamous subgroup be reconciled with the lack of benefit in the squamous cell carcinoma subgroup in the TROPION-Lung01 trial?
Key Response
The trial demonstrated a clear benefit in nonsquamous NSCLC (PFS HR 0.63), while the squamous subgroup actually trended toward favoring docetaxel (PFS HR 1.38). This suggests a biological divergence in TROP2 dependency or ADC processing between histologies. For a fellow, this underscores the importance of histology-driven treatment selection in the second-line setting and suggests that TROP2 expression levels or internalization rates may differ significantly across NSCLC subtypes.
Given that TROPION-Lung01 met its primary endpoint for PFS but failed to demonstrate a statistically significant improvement in overall survival (OS), how does this affect the clinical value proposition of replacing docetaxel as the second-line standard of care?
Key Response
While PFS was significantly improved (especially in nonsquamous patients), the lack of OS benefit (HR 0.94 in the final analysis) creates a clinical dilemma. The attending must weigh the 'quality of life' benefit—derived from a more favorable safety profile (fewer hematologic toxicities) and delayed progression—against the lack of a proven survival advantage. This necessitates a shared decision-making approach, prioritizing either toxicity management or survival outcomes depending on the individual patient's goals.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The TROPION-Lung01 study utilized a dual primary endpoint (PFS and OS) in an all-comers population. What are the statistical and design implications of the observed heterogeneity in the nonsquamous vs. squamous subgroups for future ADC trial designs?
Key Response
The marked difference in efficacy between histologies suggests that 'all-comer' designs may dilute the treatment effect of ADCs if the target biology varies by subtype. Future research should investigate if TROP2 mRNA or protein expression levels are predictive biomarkers, and whether future Phase III trials should be stratified or exclusively limited to nonsquamous populations. This highlights a need for better patient selection strategies (biomarkers) rather than relying solely on anatomic histology.
As a reviewer, how would you address the clinical significance of the primary endpoint 'success' in this trial, given the magnitude of the PFS benefit was only 0.7 months in the intention-to-treat population?
Key Response
A journal editor would flag that while the HR of 0.75 was statistically significant, the median PFS improvement (4.4 vs 3.7 months) is modest. This raises questions about the 'meaningful' clinical benefit. A tough reviewer would also scrutinize whether the nonsquamous subgroup analysis was pre-specified with sufficient power or if it was an exploratory finding used to salvage a trial that was largely negative in the squamous population.
Should the TROPION-Lung01 data lead to a change in the NCCN or ASCO guidelines for second-line NSCLC, specifically regarding the 'preferred' status of docetaxel?
Key Response
Current guidelines (e.g., NCCN) recommend docetaxel with or without ramucirumab. While Dato-DXd showed improved PFS and better tolerability in nonsquamous patients, the lack of OS benefit makes it difficult to designate it as a superior 'Category 1' recommendation over the existing standard. The committee would likely consider it as a histology-specific option for nonsquamous patients who are poor candidates for the hematologic toxicity of docetaxel, but may wait for further data on subsequent ADCs before a full-scale replacement of docetaxel.
Clinical Landscape
Noteworthy Related Trials
KEYNOTE-010
Tested
Pembrolizumab
Population
Advanced NSCLC with PD-L1 expression
Comparator
Docetaxel
Endpoint
Overall survival
OAK Trial
Tested
Atezolizumab
Population
Previously treated advanced NSCLC
Comparator
Docetaxel
Endpoint
Overall survival
DESTINY-Lung01
Tested
Trastuzumab deruxtecan
Population
HER2-mutant metastatic NSCLC
Comparator
None (single arm)
Endpoint
Objective response rate
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis